← All trials
NCT05509868
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 20, 2022
- Primary completion
- Dec 26, 2022
- Completion date
- Dec 30, 2022
- First posted
- Aug 22, 2022
- Last posted
- Aug 22, 2022
- Enrollment
- 225
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pharmbio KoreaLead sponsor
- University of UlsanOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.